Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality

• Published in: Ophthalmology (Rochester, Minn.) Vol. 130; no. 12; pp. 1258 - 1268
• Main Authors: Kempen, John H, Newcomb, Craig W, Washington, Terri L, Foster, C Stephen, Sobrin, Lucia, Thorne, Jennifer E, Jabs, Douglas A, Suhler, Eric B, Rosenbaum, James T, Sen, H Nida, Levy-Clarke, Grace A, Nussenblatt, Robert B, Bhatt, Nirali P, Lowder, Careen Y, Goldstein, Debra A, Leiderman, Yannek I, Acharya, Nisha R, Holland, Gary N, Read, Russell W, Dunn, James P, Dreger, Kurt A, Artornsombudh, Pichaporn, Begum, Hosne A, Fitzgerald, Tonetta D, Kothari, Srishti, Payal, Abhishek R, Daniel, Ebenezer, Gangaputra, Sapna S, Kaçmaz, R Oktay, Liesegang, Teresa L, Pujari, Siddharth S, Khachatryan, Naira, Maghsoudlou, Armin, Suga, Hilkiah K, Pak, Clara M, Helzlsouer, Kathy J, Buchanich, Jeanine M
• Format: Journal Article
• Language: English
• Published: United States 01.12.2023
• Subjects: Adalimumab; Alkylating Agents; Antimetabolites; Azathioprine; Calcineurin Inhibitors; Cohort Studies; Cyclosporine - therapeutic use; Humans; Immunosuppression Therapy; Immunosuppressive Agents - adverse effects; Infliximab; Methotrexate; Mycophenolic Acid - therapeutic use; Neoplasms - drug therapy; Retrospective Studies; Tumor Necrosis Factor Inhibitors; Tumor necrosis factor inhibitor; Immunosuppression; Cancer mortality; Mortality; antimetabolite

To determine the incidence of all-cause and cancer mortality (CM) in association with immunosuppression. Retrospective cohort study at ocular inflammatory disease (OID) subspecialty centers. We harvested exposure and covariate data retrospectively from clinic inception (earliest in 1979) through 201...